Search
Sodium hydroxide
go.drugbank.com/drugs/DB11151ApprovedIt is commonly found in commercial drain/ oven cleaners [L1965]. … According to the the FDA, sodium hydroxide is considered a direct food recognized as safe, where it serves as a pH control agent and follows good manufacturing guidelines [L1967].
Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% EChondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceuticalChondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, a...
ATG002
go.drugbank.com/drugs/DB05068InvestigationalATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process.
Corticorelin
go.drugbank.com/drugs/DB05394InvestigationalHuman corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.
Resolvin E1
go.drugbank.com/drugs/DB13105InvestigationalResolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalFrom this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. … Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
ALKS 27
go.drugbank.com/drugs/DB05752ExperimentalStudy showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
Genistein
go.drugbank.com/drugs/DB01645InvestigationalIt has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].
Mixtures: OSMEGA 600 MG/400 IU/25 MG EFERVESAN TABLET, 30 ADET, CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADET